Publicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (176)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke

    Frontiers in Neurology, Vol. 14

  3. Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium

    PLoS ONE, Vol. 18, Núm. 1 January

  4. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

    Genome Medicine, Vol. 15, Núm. 1

  5. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  6. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  7. Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

    Clinical Cancer Research, Vol. 29, Núm. 21

  8. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742

  9. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

    Journal of Acquired Immune Deficiency Syndromes, Vol. 93, Núm. 1, pp. 42-46

  10. Consensus Recommendations for Standardized Data Elements, Scales, and Time Segmentations in Studies of Human Circadian/Diurnal Biology and Stroke

    Stroke, Vol. 54, Núm. 7, pp. 1943-1949

  11. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  12. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

    Breast, Vol. 67, pp. 94-101

  13. First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

    Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 11, pp. 581-585

  14. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

  15. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688

  16. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

    British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147

  17. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185